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Introduction: In South Africa postpartum women have been shown to be at high risk of 
disengagement from HIV care and postpartum mobility may be related to disruptions in care. This 
study aimed to describe patterns of mobility, and explore associations with viral suppression and 
retention in the postpartum period. 
 
Methods: This study used data from a prospective cohort study that enrolled women who initiated 
life-long antiretroviral therapy (ART) during their pregnancy in Gugulethu, Cape Town (March 
2013 - June 2014), and an additional follow-up study at approximately 4 years postpartum. Patterns 
of self-reported mobility between delivery and the 4 year measurement visit were examined. Log-
binomial models were used to explore the association between mobility (moving in the 3, 6 or 12 
months prior to the study visit) and i) viral suppression (viral load (VL) ≤50 and ≤1000 copies/mL 
measured at the 12 month and 4 year measurement visit) and ii) retention in care (based on routine 
medical record data at approximately 12 months and 4 years postpartum). 
 
Results: Among the 353 women in this analysis, 98 (28%) reported having ever moved between 
delivery and 4 years postpartum. Mobility was more likely to occur soon after delivery with 50% 
of the moves occurring within the first year following delivery; the most common reason for 
moving being to live with and receive support from family (44%). Moving within 3 months of the 
viral load measurement at 12 months postpartum was associated with having a VL≤50 copies/mL 
(aRR=1.61, 95% CI: 1.17-2.21). Moving in any window prior to the 12 month or 4 year postpartum 
viral load was not associated with viral suppression. Retention in care at both 12 months and 4 
years postpartum was not associated with mobility. 
 
Conclusions: These results demonstrate that movement following delivery is a common 
occurrence among postpartum women, but this movement did not seem to disrupt engagement in 
HIV care. There is a need for further research to understand the impact of this movement on 
postpartum women’s viral suppression and retention in care, as well as on ways to support 
continued engagement in HIV care after delivery. 
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Protocol Synopsis 
Background: Consistent retention in HIV care, specifically in the postpartum period, is a 
significant challenge in South Africa [1,2]. Postpartum women living with HIV have been 
consistently shown to be at high risk of disengagement from HIV care, particularly right after 
delivery [2,3]. One reason that postpartum women have a high risk of disengagement from care 
could be due to mobility. In South Africa, postpartum women often move after delivery to seek 
help with the baby from their family, as well as to return to work [1,4]. This type of mobility may 
introduce challenges to continued engagement with HIV care and optimal antiretroviral therapy 
(ART) adherence. However, research on the topic of postpartum mobility and its impact on HIV 
care engagement and treatment outcomes. 
 
Methods: This proposed research will be a secondary data analysis of data drawn from a 
prospective cohort study, the Maternal and Child Health Antiretroviral Therapy study (MCH-ART, 
HREC REF 451/2012) and a follow-up cross-sectional study in the same cohort, the Long-term 
Adherence and Care Engagement study (LACE, HREC REF 866/2016) conducted at a primary 
healthcare facility in Gugulethu, Cape Town, South Africa. 
 
The main objectives of this research are to (i) describe postpartum movement patterns, reasons for 
this movement among women in the MCH-ART and LACE studies, and to (ii) investigate the 
impact postpartum mobility has on viral suppression and retention in care, respectively.  
 
Ethical Considerations: The MCH-ART and LACE studies received ethical approval from the 
University of Cape Town Human Research Ethics Committee and the Columbia University 
Institutional Review Board. As this study is secondary data analysis, there will be no direct contact 
with the participants of the primary studies. An anonymised dataset will be provided for analysis. 
 
Outcomes: The evidence gained from this proposed research will contribute to the limited 
literature on postpartum women’s mobility and how their mobility effects HIV treatment 
engagement and outcomes. 




Population mobility has been identified as a key driver in the spread of HIV in sub-Saharan Africa 
[5]. Mobility may be associated with HIV acquisition, with reports showing higher HIV prevalence 
among mobile populations [6–9]. In South Africa population mobility is a frequent occurrence, 
with most mobility being classified as internal migration characterized by movement within South 
Africa between rural and urban areas [8]. More recently, there has been growing concern 
surrounding the impact of frequent mobility and movement on engagement in HIV care [1].  
 
Access to antiretroviral therapy (ART) in South Africa has increased significantly over the past 
decade, with the country housing the world’s largest ART program [10]. Specifically, the increased 
uptake of ART during pregnancy for women living with HIV has helped reduce mother-to-child 
transmission (MTCT) and improve maternal health outcomes [11]. These potential benefits of 
ART use during pregnancy and the postpartum period can be undermined by poor adherence and 
disengagement from HIV care, which could result in the increased risk of drug resistance, 
treatment failure, failure to achieve viral suppression, and subsequently, MTCT, maternal 
morbidity and mortality [12,13]. Despite the importance of remaining adherent to ART and 
engagement with HIV care, many women living with HIV are not retained in care or adherent to 
ART.   
 
In South Africa, consistent retention in HIV care, specifically in the postpartum period, is a 
significant challenge [1,2]. Postpartum women living with HIV have been consistently shown to 
be at high risk of disengagement from HIV care, particularly right after delivery [2,3]. One reason 
that postpartum women have a high risk of disengagement from care could be due to mobility 
following delivery. In South Africa, postpartum women are highly likely to move after delivery to 
seek care and help with the baby from their family, as well as to return to work [1,4]. This type of 
mobility may introduce many challenges to continued engagement with HIV care and optimal 
ART adherence.  
 
These findings emphasize the need for a better understanding of postpartum mobility and its 
impact on the gains of continuous ART adherence and engagement in care. However, research on 
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the topic of postpartum mobility and its impact on retention in care and ART adherence is scarce 
despite it being a significant cause for concern.  
 
Background for proposed dissertation  
The proposed dissertation will be a secondary analysis of data collected from the Maternal and 
Child Health Antiretroviral Therapy (MCH-ART) study, a prospective cohort study conducted at 
a primary healthcare facility in Gugulethu, Cape Town, that took place between March 2013 and 
June 2014. The study focussed on evaluating two strategies for delivering HIV care to postpartum 
women living with HIV and their HIV exposed infants [14]. A follow-up to the MCH-ART study, 
the Long-term Adherence and Care Engagement (LACE) study, examined long-term adherence 
and engagement in care among the MCH-ART study participants approximately 4 years 
postpartum. This proposed dissertation will focus on the aspect of mobility and movement in the 
postpartum period and the associations that exist between mobility and viral suppression and 
retention in HIV care. 
 
Study Rationale 
Postpartum retention in care in South Africa is a significant challenge, with numerous studies 
reporting that disengagement from HIV care occurs more frequently during the postpartum period 
in comparison to antenatal care (ANC) [2,15]. Mobility has been identified as a possible risk factor 
for care disengagement in postpartum women living with HIV [1]. In South Africa, postpartum 
women often move after delivery to receive support and care from their family members or 
caregivers [1,2]. Postpartum mobility therefore presents a challenge to continued HIV care access 
with potential impacts on viral suppression and retention in care.  
 
Research focusing on postpartum mobility and its effects on viral suppression and engagement 
with HIV care in South Africa is scarce. Majority of mobility related research focusses on mobility 
as a risk factor for HIV acquisition and its influence on access to HIV care [7]. There is a need to 
understand the patterns of mobility among postpartum women living with HIV and the associations 
that exist between mobility and engagement in HIV care. However, these data have not previously 
been described in our setting.  
 




Increased access to and uptake of ART during pregnancy for women living with HIV in recent 
years has helped reduce MTCT and improve maternal health outcomes [16]. Despite this 
accomplishment and the importance of remaining adherent to ART, postpartum women have been 
shown to be at high risk of disengagement from HIV care [2,17]. A factor that influences this 
disengagement that has been identified in research is mobility that commonly takes place following 
delivery of the baby [1,17]. This type of mobility may introduce many challenges to continued 
engagement with HIV care and optimal ART adherence. Based on these findings, this dissertation 
aims to investigate the impact of mobility during the postpartum period on viral suppression and 
retention in HIV care among postpartum women living with HIV. To inform this research, this 
literature review aims to evaluate existing literature on the influence of mobility on ART adherence 




The literature search was done electronically to identify relevant literature focussed on mobility or 
mobile populations living with HIV, their experiences regarding mobility and their engagement 
with HIV care and ART adherence. The search was conducted on PubMed and Google Scholar. 
The search strategy included combinations of the search terms and their synonyms that are 
presented in Box 1. Studies were only included in the review if population mobility or some aspect 
of mobility such as clinic transfers or movement between clinics was evaluated, and the outcome 
of interest was a measure used to assess HIV care engagement or ART adherence.  
 
Box 1: Literature review search strategy terms 
HIV: Human immunodeficiency virus 
Mobility: Migrant, migration, migrate, relocate, relocation, travel 
Engagement: Disengagement, lost to follow-up, retention, retained, non-retention 
Adherence: Adherence, non-adherence, compliance, non-compliance, viral load, viral 
suppression 
Postpartum:  Maternal, perinatal, postnatal 
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Results 
The impact of mobility on HIV care cascade outcomes 
Delays in HIV diagnosis and accessing or seeking care 
In South Africa mobility is a frequent occurrence with movement between rural and urban areas 
or between provinces being the most common type of mobility in the country [18].  Individuals 
living with HIV’s interaction with HIV care is likely to reflect their timing and patterns of 
movement [7,19]. A review on literature that focussed on migrants and their interaction with HIV 
care showed that migrants and mobile populations were more likely to enter into the healthcare 
system and HIV care later than non-migrants [7]. Research has shown that regular movement 
disrupts opportunities for HIV care access [17]. Mobile populations are therefore likely to 
experience delays in HIV diagnosis and treatment initiation, which could have negative effects on 
HIV treatment as prevention outcomes.  
 
Mobility’s effect on engagement with and retention in HIV care 
Once they have been linked to HIV care, mobile populations also face many barriers to being 
retained in care. Regular travel makes it difficult for mobile individuals to remain enrolled in HIV 
care at a specific clinic, and also impacts their ability to access medication [7,17]. Mobile 
individuals are therefore more likely to be lost to follow-up (LTFU) than non-mobile individuals. 
A study on adult patients initiating ART in Lesotho reported that one year following ART 
initiation, migrant patients had a 6.69-fold increased rate of being LTFU in comparison to non-
migrant patients [20].  
 
Reengagement with HIV care following LTFU due to mobility or clinic transfer has also been 
shown to be suboptimal in current literature, with Hickey and colleagues [21] reporting that for 
patients who transferred out or were LTFU, the cumulative incidence of reengagement with care 
was 14% at 3 months following LTFU and 60% at 6 months following LTFU. These findings 
suggest that mobility plays a role in disrupting HIV care engagement, as well as hampers 
reengagement with care.  
 
Mobility is also associated with and facilitates many of the barriers that hinder or delay 
engagement with HIV care. These barriers included fear of HIV-related stigma from the public at 
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the new location and clinic, unfamiliarity with the new environment and structural factors such as 
the long distance to the clinic and the cost of transportation [6,7,17]. While mobility can influence 
many barriers to care, some studies have also made evident that an interplay between mobility and 
barriers to HIV care engagement exists, with some barriers also prompting mobility. It has been 
shown that traveling for care and transfer to different clinics was sometimes influenced by the 
desire to avoid stigma in one’s hometown as well as to seek anonymity in terms of receiving HIV 
care [6,16,22]. 
 
Furthermore, mobile populations also have different health-seeking behaviours with some studies 
reporting that mobile individuals are more likely to seek care only once they experienced 
symptoms or felt unwell [7]. More research on mobile populations and how they interact with HIV 
care is therefore necessary in order to better understand their behaviour in terms of HIV care 
engagement. 
 
Effect of mobility on ART adherence 
Disruptions to ART and treatment adherence were also common among individuals who would 
regularly travel. Numerous studies found that individuals that were mobile would report poor 
medication adherence behaviours when travelling [20,23–25]. This suboptimal treatment 
adherence can result in poor treatment outcomes [26]. A study conducted in East Africa looking 
at treatment outcomes between permanent residents and non-residents found that non-residents 
were less likely to be virally suppressed in comparison to residents (64% versus 84% virally 
suppressed) [24]. Similarly, a study conducted among isiZulu speaking adults living with HIV in 
South Africa reported that 19% of in-migrants and 26% of out-migrants were virally suppressed 
on the date at which they migrated into or out of the community in comparison to approximately 
50% of non-migrants being virally suppressed [23].  
 
The main barriers to complete ART adherence expressed by individuals were fear of medication 
side-effects while travelling, delaying taking of medication until they had reached their destination, 
and stigma-related fear of disclosure of HIV status when taking medication in public and around 
family members [6,7,19,27]. Taylor and colleagues [6] also identified interruptions in adherence 
due to a limited medication supply as a dominant barrier to adherence, especially during longer 
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journeys. This research suggests that barriers created by mobility and travel could negatively 
impact ART adherence, which could lead to poor treatment outcomes. This emphasizes the need 
for HIV care to consider mobile populations in order to address issues of ART adherence and HIV 
care engagement.  
 
Mobility and its impact on HIV care cascade outcomes for postpartum women 
Many studies that have evaluated possible reasons for the high risk of disengagement from HIV 
care in postpartum women have shown that an important factor that impacts engagement with care 
is mobility [28–30]. However, studies that focussed specifically on postpartum women’s mobility 
were scarce, with only three studies being identified, one of which focussed on motivations for 
postpartum mobility while the other two focussed on movement between clinics in terms of linkage 
to care and LTFU.  
 
Motivations for postpartum mobility and engagement with HIV care 
Clouse and colleagues [1] sought to explore South African peripartum women’s mobility in an 
effort to understand timing and motivations of travel. In line with the results of earlier studies 
evaluating postpartum engagement in care, they found that nearly all of their participants planned 
to travel after delivery of the baby [1]. The main motivations for this travel was to visit family to 
seek care and help with the baby, or to return to work in Johannesburg if they were employed [1]. 
The majority of participants also expressed their intention to continue HIV care following delivery, 
however care for the infant was often emphasized over care for the mother [1]. Of those 
participants who travelled, few had planned to seek care at the new location they would be 
travelling to [1]. This is a cause for concern as continuous engagement in HIV care and optimal 
treatment adherence is necessary to decrease the risk of HIV transmission and MTCT through 
breastfeeding, treatment failure and subsequent poor health outcomes.  
 
Mobility in the form of transfer of care or lost to follow up 
Another reason for high postpartum mobility is the clinic transfer process that occurs after delivery 
of the baby. In South Africa, women living with HIV who have not started ART are placed on 
treatment during their pregnancy in integrated clinics that provide both HIV care and ANC [13]. 
However, following delivery women are required to transfer their HIV care and link to general 
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ART clinics [3]. This transfer process presents challenges to retaining women in HIV care and 
results in women being LTFU. Two studies in South Africa have shown that linkage to care for 
postpartum women in South Africa during this transfer process is poor, with a significant 
proportion of women not linking to care at all, or those that do link not being retained long-term 
[3,16]. 
 
Challenges of measuring retention and adherence in mobile populations 
Mobility also presents a challenge for measuring patient retention in care and adherence. 
Movement between clinics is difficult to track in South Africa as health facilities are often not 
linked through electronic medical records [16]. Therefore, it is a challenge to determine whether a 
patient has completely disengaged from care or has sought care at a different clinic [31]. A study 
on mobility and clinic switching among postpartum women conducted in South Africa showed 
evidence of 38% of women thought to be LTFU continuing HIV care at other clinics either within 
the same province as the original clinic or in other provinces in South Africa [16]. Therefore, 
estimates of LTFU may not represent true disengagement from care, and instead represents patient 
drop-out from a specific clinic.  
 
It is therefore important to account for patient mobility and movement between clinics as failure 
to do so could result in the under- or over-estimation of retention in care estimates. Fox and 
colleagues [22], comparing retention in care from the clinic perspective (what most studies report) 
to retention from the national perspective (which accounts for movement between clinics) in South 
Africa, found that retention was considerably higher when evaluated from a national perspective 
in comparison to a clinic perspective. This research suggests that retention and LTFU estimates 
taken from the perspective of a clinic, and which fails to account for patient movement between 
clinics, underestimates retention in care.  
 
Conclusion and Gaps in Research  
Based on the studies discussed in this literature review, mobility may lead to delays in seeking 
care and HIV diagnosis which increases the risk of HIV transmission and poor health outcomes. 
Studies have also shown that mobility negatively impacts engagement with and retention in HIV 
care, as well as interferes with optimal adherence to ART. Despite these findings, research on the 
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impact of mobility on HIV care engagement and ART adherence is scarce and few studies were 
identified that focussed on postpartum mobility and its effects of postpartum engagement with 
care. This is a cause for concern as consistent retention in HIV care is a significant challenge in 
South Africa and postpartum women are at high risk of disengaging from care [1,2]. This literature 
review’s findings emphasize the need for more research on postpartum mobility and its impact on 
postpartum treatment adherence and engagement in care.  
 
Given the findings in this review, this proposed research aims to evaluate postpartum women’s 
patterns of mobility and investigate the associations that may exist between mobility and viral 
suppression and retention in care. The evidence gained from this research will contribute to the 
literature on postpartum women’s mobility and how their mobility effects HIV treatment 
engagement and outcomes. 
 
 
Study aims and objectives 
Study aim 
The aim of this research is to describe postpartum movement patterns and to investigate whether 
mobility is associated with viral suppression and retention in HIV care among postpartum women 
in the LACE study.  
 
Objectives 
1. To describe the movement patterns of postpartum women in the LACE study from delivery 
to approximately 4 years postpartum. 
2. To investigate the association between mobility and viral load (VL) at two different follow-
up points in the LACE study, at 12 months and approximately 4 years postpartum.  
3. To investigate the association between mobility and retention in care using routine data 
from the LACE study, at 12 months and approximately 4 years postpartum. 
 
 




This study will be a secondary data analysis of data from a prospective cohort study (the MCH-
ART study HREC REF 451/2012) and a follow-up cross-sectional study in the same cohort (The 
LACE study HREC REF 866/2016) conducted at a primary healthcare facility in Gugulethu, Cape 
Town, South Africa. Data for this thesis will be drawn only from the MCH-ART study and the 
LACE study and no additional data will be collected.  
 
The MCH-ART study 
The Maternal and Child Health Antiretroviral Therapy (MCH-ART) study was a multi-phase 
prospective cohort study situated at the Gugulethu Midwife Obstetric Unit (MOU) in Cape Town, 
South Africa [14]. The study enrolled participants from March 2013 to June 2014 and followed up 
these participants for 18 months [14]. This study aimed to evaluate two strategies for delivering 
HIV care and treatment services to postpartum women living with HIV who initiated ART during 
pregnancy, and their HIV exposed infants [14]. 
 
The LACE study  
The Long-term Adherence and Care Engagement (LACE) study was an additional cross-sectional 
study conducted following the completion of the MCH-ART study. The study aimed to examine 
the long-term adherence and care engagement among MCH-ART study participants [32]. 
Participants who were enrolled in the postpartum cohort of the MCH-ART study were requested 




The analysis will be restricted to postpartum women living with HIV who initiated lifelong ART 
during their pregnancy and were enrolled in both the MCH-ART and LACE studies. 
 
Research Setting 
The primary studies collected data from a cohort of women based at a large antenatal clinic in 
Gugulethu, Cape Town, South Africa. Gugulethu is an area characterized by high levels of poverty, 
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unemployment and HIV [33]. ART and health services are provided free of charge in local public-
sector health care facilities [33]. All pregnant women living with HIV have been eligible to be on 
lifelong ART irrespective of their clinical stage or CD4 count since 2013 [34]. ANC coverage in 
this setting is high at 95% [33]. Women living with HIV who are pregnant are provided with 
integrated ANC and ART services and are then required to transfer to general ART clinics for 
postpartum care.   
 
Data Collection  
This secondary analysis will be using data collected during the study measurement visits carried 
out in the MCH-ART and LACE studies. These measurement visits consisted of VL testing and 
the administration of questionnaires (Appendix A) to collect demographic information [14]. In the 
LACE study, maternal movement tables (Appendix B) were used to collect data on participants’ 
mobility patterns and reasons for this mobility [32]. Specifically, the maternal relocation table 
which described movement after the delivery of the baby will be used in this secondary analysis. 
Additional data was also drawn from routine medical records obtained from the Western Cape 
Department of Health’s Provincial Health Data Centre (PHDC). Using the provincial unique 
patient identifier, the PHDC is able to link participants healthcare access across all public facilities 
in the Western Cape [35]. These records will provide data on ART initiation and follow up in 




Population mobility has been identified as a key risk factor for HIV infection [8]. Mobility is also 
increasingly being recognized as a potential barrier to HIV care [19]. There is great variation in 
the definitions for mobility in current HIV literature. This is due to mobility being a broad term 
encompassing many aspects of population movement [19]. Definitions include permanent 
migration, temporary mobility, frequent and repetitive migration, cross-border migration and 
internal migration [19,36]. This variation in definitions of mobility in literature has led to 
inconsistent findings about mobility as a risk factor for HIV [8,19]. 
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Broadly, in this study mobility will be based on women’s self-report of movement to new locations 
following delivery. Mobility as an exposure will be analysed as a binary variable, as either having 
moved within 3, 6 or 12 months of the measurement visit or having not moved during this time 
period. Among women who move, movement will also be characterised as movement into or out 
of the home area (Gugulethu), as well as movement within and out of the Western Cape. 
 
Adherence and viral load 
There are many methods that exist in the literature for measuring and defining treatment adherence, 
however there is currently no gold standard measure of adherence [37]. VL is often used as a proxy 
measure for treatment adherence and is considered a standard measure for treatment success [37]. 
While VL is commonly used as a proxy measure for adherence, it can be influenced by multiple 
factors other than adherence such as treatment resistance [38]. Nonetheless treatment success is 
often determined by a patient’s VL [38]. In this analysis VL will be used as a proxy measure for 
adherence. The outcome of viral suppression will be defined as VL thresholds of ≤50 copies/mL 
and ≤1000 copies/mL based on routine guidelines [13].  
 
Retention in care 
As with adherence there are various methods that can be used to measure retention in care. Timely 
linkage to and retention in care is imperative for the success of HIV treatment, as it allows for 
access to ART [39]. Adequate access to ART and HIV care is essential to attain a high level of 
adherence to achieve and sustain viral suppression [39]. Despite the recognized importance of 
retention in care for treatment success in the literature, no gold standard measure currently exists 
[39].  
 
For this study, a cross-sectional definition of retention in care will be used. Retention will be 
defined as at least one contact with routine HIV care during a specific window of time [40].  In 
this secondary analysis, retention in care at 12 months postpartum was measured using routinely 
collected medical records and defined as evidence of an HIV-related clinical contact for the period 
9-18 months postpartum. We will also measure retention at the LACE visit, approximately 4 years 
postpartum. 
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Data Management and Analysis Plan 
Data Management  
As per the MCH-ART and LACE study protocols, data that was collected was entered into a 
password-protected Microsoft Access database. Database files stored on the University of Cape 
Town (UCT) firewall protected network drive. Anonymous participant identification numbers 
were used, except for provincial data, with no participant names or identifiers being attached to 
participant data. For provincial data, identifiers had to be collected in order to link the routine data. 
Once linked the identifiers were removed and the data is now identified using only the unique 
participant identifier. Anonymised data for analysis will be shared as an encrypted file using the 
UCT file sender or on a password protected external hard drive. 
 
Descriptive Analysis  
All statistical analyses will be done in Stata 15 (Stata Corporation, College Station, Texas). Initial 
exploration of all variables will be done to identify missing data and any patterns related to missing 
data. Descriptive statistics will be used to describe the demographic and clinical characteristics of 
the study participants. This analysis will include means and standard deviations, frequencies and 
proportions or medians with interquartile ranges with chi-squared tests, Fisher’s exact tests, rank 
sum tests or t-tests, as will be appropriate for the variables of interest. 
 
Patterns of Mobility 
Data collected on the maternal movement of the postpartum women in the study will be analysed 
to detect any patterns of movement for our first objective. To describe the patterns of mobility in 
the study, descriptive statistics summarising different aspects of participant mobility will be used. 
This will include: number of times moved, the area of movement, timing of movement, and reasons 
for moving. Movement into and out of the host clinic’s area (Gugulethu), as well as movement 
within and out of the province (Western Cape) will also be considered.  
 
The Effect of Mobility on Viral Suppression and Retention in Care  
For the second objective, the primary outcome of interest is viral suppression which will be defined 
as viral thresholds of ≤50 copies/mL and ≤1000 copies/mL. Log-binomial regression models will 
be used to identify predictors of viral suppression for both thresholds, with variables being 
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included as predictors if they are considered to be associated with viral suppression based on 
previous literature within the limits of the data that has been collected, as well as the bivariate 
analysis. Log-binomial regression models will be run to identify predictors at each time point, 12 
months and 4 years postpartum, to assess the associations that exist for each time point separately. 
In particular, the association between mobility in the past 3, 6 and 12 months before the 
measurement visit and VL will be explored.  
 
The third objective’s primary outcome of interest is retention in care, which is defined as at least 
one contact with routine HIV care at approximately 12 months postpartum, as well as retention at 
the LACE visit approximately 4 years postpartum. The included participants in this analysis will 
be restricted to a subset of women who did not report leaving the province (Western Cape). The 
reason for this is that the routine data used to measure retention is only available from facilities in 
the Western Cape. Variables will be included as predictors in the model based on previous 
literature within the limits of the data that has been collected, and the bivariate analysis. In 
particular, the association between mobility in the past 3, 6 and 12 months before the measurement 
visit and retention will be explored.  
 
For these analyses, risk ratios and adjusted risk ratios with 95% Confidence Intervals (CI) will be 
reported. Statistical significance for these exploratory analyses will be set at an α-level of 0.10 to 




The MCH-ART and LACE studies received ethical approval from the University of Cape Town 
Human Research Ethics Committee and the Columbia University Institutional Review Board 
(Appendix C and D). As this study is secondary data analysis, there will be no direct contact with 
the participants of the primary studies.  
 
Consent 
All women enrolled in the primary studies completed written informed consent which included 
consent to review their routine medical records and consent to be contacted for future research 
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As this is secondary analysis, there are no direct risks for this study as there is no direct contact 
with the primary study’s participants. Nonetheless, a possible risk in this research is a breach of 
confidentiality, however many measures will be taken to ensure that study participants will remain 
anonymous during the study period.  
 
Benefits 
As this research is secondary analysis, there are no direct benefits to the primary study’s 
participants. However, this study aims to contribute to the limited research on mobility and 
postpartum women’s engagement with HIV care. This study aims to further understanding and 
knowledge of patterns of mobility among postpartum women living with HIV and the influence 
of mobility on postpartum engagement in HIV care.  
 
Confidentiality  
For this secondary analysis there will be no contact with the primary study’s participants, however 
efforts will be made to protect participant confidentiality at all times during the study process. No 
participant identification information will be attached to participant data, and anonymous 
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Timeframe 
Table 1: Timeframe for study activities  
 Feb 2020 Mar 2020 Apr 2020 May 2020 June 2020 
Protocol submission      
Data Analysis      
Manuscript Write-up      
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Abstract 
Introduction: In South Africa postpartum women have been shown to be at high risk of 
disengagement from HIV care and postpartum mobility may be related to disruptions in care. This 
study aimed to describe patterns of mobility, and explore associations with viral suppression and 
retention in the postpartum period. 
 
Methods: This study used data from a prospective cohort study that enrolled women who initiated 
life-long antiretroviral therapy (ART) during their pregnancy in Gugulethu, Cape Town (March 
2013 - June 2014), and an additional follow-up study at approximately 4 years postpartum. Patterns 
of self-reported mobility between delivery and the 4 year measurement visit were examined. Log-
binomial models were used to explore the association between mobility (moving in the 3, 6 or 12 
months prior to the study visit) and i) viral suppression (viral load (VL) ≤50 and ≤1000 copies/mL 
measured at the 12 month and 4 year measurement visit) and ii) retention in care (based on routine 
medical record data at approximately 12 months and 4 years postpartum). 
 
Results: Among the 353 women in this analysis, 98 (28%) reported having ever moved between 
delivery and 4 years postpartum. Mobility was more likely to occur soon after delivery with 50% 
of the moves occurring within the first year following delivery; the most common reason for 
moving being to live with and receive support from family (44%). At 12 months postpartum, 
women who moved within 3, 6 or 12 months of the viral load measurement were more likely to be 
virally suppressed. Moving in any window prior to the 4 year postpartum viral load was not 
associated with viral suppression. Retention in care at both 12 months and 4 years postpartum was 
not associated with mobility. 
 
Conclusions: These results demonstrate that movement following delivery is a common 
occurrence among postpartum women, but this movement did not seem to disrupt engagement in 
HIV care. There is a need for further research to understand the impact of this movement on 
postpartum women’s viral suppression and retention in care, as well as on ways to support 
continued engagement in HIV care after delivery. 
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Introduction 
Population mobility has been identified as a key driver in the spread of HIV in sub-Saharan Africa 
and studies have shown higher HIV prevalence among mobile populations [1–5]. More recently, 
there has been growing concern surrounding the impact of movement on engagement in HIV care 
[6–8]. In South Africa population mobility is a common occurrence, with most mobility being 
classified as internal migration characterized by movement between rural and urban areas within 
South Africa [5]. 
 
Increased access to and uptake of antiretroviral therapy (ART) during pregnancy for women living 
with HIV in recent years has helped reduce mother-to-child transmission and improve maternal 
health outcomes [8]. Despite this accomplishment and the importance of remaining adherent to 
ART, postpartum women are at high risk of disengagement from care, specifically following 
delivery [6,9–11]. Mobility could be one reason for postpartum women’s disengagement from care 
following delivery. In South Africa, women often move after delivery to seek care and help with 
the baby from their family, as well as to return to work [2,6,12,13]. Additionally, women are 
required to transfer their HIV care and link to a  general ART clinic after delivery and this has 
been shown to present a significant challenge to retaining women in care [6,10]. These types of 
mobility may introduce many challenges to continued engagement with care and optimal ART 
adherence. Despite these findings, research focusing on postpartum mobility and its effects on 
viral suppression and retention in care is scarce. Most mobility related research focusses on 
movement as a risk factor for HIV acquisition and its influence on access to HIV care, with little 
focus on postpartum women’s experiences of mobility and HIV care.  
 
To address this gap in the literature, we examined patterns of movement and engagement with 
HIV care up to 4 years postpartum. The objectives were (i) to describe movement patterns of 
postpartum women from delivery to approximately 4 years postpartum and (ii) to explore whether 
movement was associated with viral suppression and retention in care at approximately 12 months 
and 4 years postpartum.  
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Methods 
Study design and setting 
This is a secondary data analysis of women living with HIV who initiated lifelong ART during 
their pregnancy and were enrolled in both the Maternal and Child Health Antiretroviral Therapy 
(MCH-ART) and the follow-up Long-term Adherence and Care Engagement (LACE) studies 
[14,15]. The MCH-ART study aimed to evaluate two strategies for delivering HIV care and 
treatment services to postpartum women and their HIV-exposed infants [14]. The LACE study 
was an additional follow-up visit which aimed to examine long-term adherence and care 
engagement among MCH-ART study participants [15].   
 
These studies were conducted at a primary healthcare facility in Gugulethu, Cape Town, South 
Africa. Gugulethu is an area characterized by high levels of poverty, unemployment and HIV [16]. 
Antenatal care (ANC) coverage in this setting is high at 95% [16]. ART and health services are 
provided free of charge in local public-sector care facilities. Since 2013, all pregnant women living 
with HIV are eligible to be on lifelong ART irrespective of their clinical stage or CD4 count [17]. 
Pregnant women living with HIV are provided with integrated ANC and ART services and are 
then required to transfer to general ART clinics after delivery for postpartum care. 
 
Data sources 
This analysis used data collected during the study measurement visits conducted throughout the 
MCH-ART and LACE studies. The MCH-ART study enrolled pregnant women who presented for 
ANC at the integrated clinic from March 2013 to June 2014 and followed-up these women for 18 
months. For the LACE study, participants who were enrolled in the postpartum cohort of the MCH-
ART study were requested to return for one additional study visit that would take place between 
36 and 60 months postpartum. The sample at baseline for the MCH-ART study was 471 women. 
The proportion of the baseline sample was 87% at 12 months postpartum (n=411) and 75% at 
approximately 4 years postpartum (n=353).  
 
The measurement visits were conducted separate from routine care and consisted of viral load 
(VL) testing and the administration of questionnaires to collect demographic information. 
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Additionally, in the LACE study maternal movement tables were used to collect self-report of 
participants’ mobility following delivery.  
 
Additional data was drawn from routine medical records obtained from the Western Cape 
Department of Health’s Provincial Health Data Centre [18]. These records provided data on ART 
initiation and follow-up in routine care for all women enrolled in the MCH-ART study. The 
provincial unique patient identifier makes it possible to link participants’ healthcare access across 
all public facilities in the Western Cape.   
 
Measurements 
The main constructs that this analysis sought to measure were mobility, viral suppression, and 
retention in HIV care. Mobility was based on women’s self-report of movement to a new location 
following delivery. All movement after delivery was described. The primary exposure was 
analyzed as a binary variable, defined as either having moved or not in windows of 3, 6 or 12 
months prior to the outcome measurement. 
 
Outcome measures: 
Outcomes were assessed at approximately 12 months postpartum (the primary MCH-ART 
timepoint) and approximately 4 years postpartum (at the LACE visit). VL and retention in HIV 
care were assessed. Viral suppression was defined as VL thresholds of ≤50 and ≤1000 copies/mL 
based on routine guidelines [19]. Retention in care at 12 months postpartum was defined as 
evidence of an HIV-related clinical contact for the period 9-18 months postpartum. Retention in 
care was also measured at the LACE visit at approximately 4 years postpartum.   
 
Data analysis  
All data analyses were done in Stata 15 (Stata Corporation, College Station, Texas). Descriptive 
statistics were used to describe the demographic and clinical characteristics of study participants. 
This analysis used means and standard deviations (SD), frequencies and proportions or medians 
and interquartile ranges (IQR), with chi-squared tests, Fisher’s exact tests, t-tests or rank sum tests 
where appropriate for the variables of interest.  
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Patterns of postpartum movement were described using descriptive statistics summarizing 
different aspects of participant mobility, including frequency and timing of movement, reasons for 
movement, and area of movement.   
 
Log-binomial regression models were used to examine the association between mobility which 
occurred in the past 3, 6 or 12 months and each outcome, viral suppression and retention in care, 
respectively. Inclusion of covariates in the models followed a stepwise model building approach 
and was based on findings in previous literature (within the limits of the data that has been 
collected) and if they reached p<0.10 in the bivariate analysis. Covariates that were included in 
models based on previous literature included age, education level, timing of HIV diagnosis and 
baseline CD4 count [3,9,20,21]. Models were run to identify predictors at approximately 12 
months and 4 years postpartum, to assess the associations that exist for each time point separately. 
The retention outcome was limited to women who did not report leaving the province (Western 
Cape) due to the routine data only being available for facilities in the Western Cape. Design effect 
was included in the models to control for any influence the MCH-ART study could have on the 
outcomes of interest. Design effect was defined as a binary variable where women were allocated 
to either the MCH-ART intervention arm or the control arm. For these analyses, unadjusted and 
adjusted risk ratios with 95% Confidence Intervals (CI) are presented. Associations below an α-
level of 0.10 were also considered in this exploratory analysis to be indicative of an effect that 
warrants further study.  
 
Ethics 
The MCH-ART and LACE studies received ethical approval from the University of Cape Town 
Human Research Ethics Committee and the Columbia University Institutional Review Board. 
Ethical approval for this secondary analysis was obtained from the University of Cape Town 
Human Research Ethics Committee. All women included in this analysis completed written 
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Results 
Overall, 353 women were eligible and included in the analysis (Table 1). Their mean age was 
32.57 years at LACE enrolment (approximately 4 years postpartum). At both MCH-ART (ANC) 
and LACE enrolment, approximately 24% of women completed secondary school and 37% were 
married or cohabiting. Over 95% of women had disclosed their HIV status to at least one person, 
therefore it was not included in the analysis. 
 
Patterns of mobility  
There were 98 women (28%) who reported having ever moved between delivery and the LACE 
study visit, with a total number of 125 moves occurring (Table 2). The median number of moves 
was 1 (IQR: 1-2), with 50% of the moves occurring within the first year following delivery. The 
most common reasons for moving were to live with and receive support from family (44%) or live 
with their partner (19%).  
 
Women who moved at least once were more likely to have had lower socioeconomic status (SES) 
(33% versus 24%) and to be living in informal housing (61% versus 48%) when they enrolled in 
the MCH-ART study, compared to women who did not move (Table 1). Women who ever moved 
were slightly younger in age than those who did not move. At LACE enrolment (approximately 4 
years postpartum), women who had ever moved were less likely to be employed (36% versus 49%) 
and were more likely to be living in formal housing (60% versus 49%) compared to women who 
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Table 1. Description of 353 postpartum women living with HIV at approximately 4 years postpartum. 
All women initiated lifelong ART during pregnancy. The table is grouped by whether women reported 
moving during the postpartum period or not. 
 
 Ever Moved Not Moved Total p-value 
Number of participants 98 (28) 255 (72) 353 (100)  
Baseline Characteristics (at MCH-ART enrolment) 
Mean Age (in years) 27.88 (4.59) 28.94 (5.71) 28.64 (5.50) 0.103 
Education    0.177 
Completed secondary school 19 (19) 67 (26) 86 (24)  
Less than secondary school 79 (81) 188 (74) 267 (76)  
Employment Status    0.315 
Employed 35 (36) 106 (42) 141 (40)  
Not employed 63 (64) 149 (58) 212 (60)  
Socioeconomic Status    0.019 
Lowest 32 (33) 62 (24) 94 (27)  
Moderate 40 (41) 84 (33) 124 (35)  
Highest 26 (27) 109 (43) 135 (38)  
Relationship    0.359 
Married/cohabiting 34 (35) 102 (40) 136 (39)  
Not married/cohabiting 64 (65) 153 (60) 217 (62)  
Housing    0.020 
Formal 38 (39) 134 (53) 172 (49)  
Informal  60 (61) 121 (48) 181 (51)  
Gravidity (Median (IQR)) 1 (1-2) 1 (1-2) 1 (1-2) 0.137 
Diagnosed with HIV in this pregnancy 58 (59) 136 (53) 194 (55) 0.322 
Postpartum Characteristics (at LACE enrolment) 
Mean Age (in years) 31.84 (4.68) 32.85 (5.77) 32.57 (5.50) 0.120 
Education    0.591 
Completed secondary school 22 (23) 64 (25.) 86 (24)  
Less than secondary school 76 (78) 190 (75) 266 (76)  
Employment Status    0.021 
Employed 35 (36) 126 (49) 161 (46)  
Not employed 63 (64) 129 (51) 192 (54)  
Socioeconomic Status    0.195 
Lowest 38 (39) 77 (30) 115 (33)  
Moderate 31 (32) 79 (31) 110 (31)  
Highest 29 (30) 99 (39) 128 (36)  
Relationship    0.304 
Married/cohabiting 33 (34) 101 (40) 134 (38)  
Not married/cohabiting 65 (66) 154 (60) 219 (62)  
Housing    0.069 
Formal 59 (60) 126 (49) 185 (52)  
Informal  39 (40) 129 (51) 168 (48)  
Gravidity (Median (IQR)) 2 (2-3) 3 (2-3) 2 (2-3) 0.478 
Currently pregnant 7 (7) 12 (5) 19 (5) 0.473 
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Table 2. Descriptive statistics of the mobility patterns of 98 postpartum women living 
with HIV who initiated ART during pregnancy who had reported moving at least once 
after delivery. 
 
Variable Ever Moved 
Number of women who ever moved 98 (78) 
Total number of moves 125 (100) 
Number of times moved (median and IQR) 1 (1-2) 
Number of times moved  
1 76 (61) 
2 18 (14) 
3 3 (2) 
4 1 (1) 
Area of movement  
Moved into Gugulethu 11 (9) 
Moved out of Gugulethu 19 (15) 
Moved within the Western Cape 55 (44) 
Moved out of the Western Cape 40 (32) 
Time of movement  
1 year postpartum 62 (50) 
2 years postpartum 31 (25) 
3 years postpartum 24 (19) 
4 years postpartum 8 (6) 
Relocation Reason  
Family 55 (44) 
Employment 4 (3) 
Partner 24 (19) 
Moved to own house 7 (6) 
Transferred HIV care 1 (1) 
Unclear 34 (27) 
 
 
Mobility and viral suppression 
VL measures were available for 349 women (98%) out of the 353 women in the study at both 
approximately 12 months and 4 years postpartum. Of these women, 66% were virally suppressed 
at 12 months postpartum, and 56% were virally suppressed at 4 years postpartum. The association 
between mobility in the 3, 6 and 12 months prior to the VL measurement, and viral suppression 
was assessed (Table 3 and 4). Bivariate associations are reported in Supplementary Table 2 and 3. 
The MCH-ART trial arm did not alter any of the associations for the VL outcomes.  
 
12 months postpartum: 
At 12 months postpartum, women who had moved within 3, 6 or 12 months of the VL 
measurement were more likely to be virally suppressed (VL≤50 and VL≤1000 copies/mL) 
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compared to women who had not moved. In bivariate analyses, those who were virally suppressed 
were slightly more likely to move within 3, 6 and 12 months of the VL measurement compared to 
those who were not virally suppressed (7% versus 4%, 8% versus 6%, 12% versus 9% 
respectively), however this difference was not statistically significant (Supplementary Table 2). 
Increasing age and having a higher CD4 cell count at MCH-ART study enrolment were both 
associated with having a VL≤50 and VL≤1000 copies/mL (Table 3). Being diagnosed with HIV 
in the current pregnancy was consistently associated with viral suppression. Having moderate SES 
increased the likelihood of having a VL≤50 (aRR=1.41, 95% CI: 1.13-1.78) and VL≤1000 
copies/mL (aRR=1.20, 95% CI: 1.00-1.44) compared to low SES (Table 3).  
 
4 years postpartum:  
Mobility in any window prior to the 4 year postpartum VL was not associated with viral 
suppression in bivariate analyses (Supplementary Table 2 and 3) or multivariable models (Table 
4). Those who were virally suppressed were less likely to have moved in the preceding 12 months 
compared to those who were not virally suppressed (6% versus 12%). However, this association 
did not persist in multivariable models and no association was observed between moving in the 
past 3 or 6 months and viral suppression. Women who were currently pregnant were more likely 
to have a VL≤50 (aRR= 1.40, 95% CI: 1.07-1.83) and VL≤1000 copies/mL (aRR=1.41, 95% CI: 
1.09-1.81). Being employed increased the likelihood of having a VL≤50 (aRR=1.24, 95% CI: 1.03-
1.48) and VL≤1000 copies/mL (aRR=1.17, 95% CI: 1.00-1.36). In the univariate model, increasing 
age increased the likelihood of having a VL≤50 copies/mL (RR=1.02, 95% CI: 1.00-1.03), 
however this association did not persist in the multivariable model.  
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Table 3. Log binomial regression model among 349 postpartum women living with HIV who initiated ART during pregnancy, predicting A) VL ≤50 copies/mL at 
approximately 12 months postpartum, and B) VL ≤1000 copies/mL at approximately 12 months postpartum. This table is grouped by whether movement occurred 3 
months, 6 months or 12 months prior to the viral load visit. Unadjusted (RR) and adjusted (aRR) risk ratios are presented with 95% confidence intervals (CI). 
 
 Moved within 3 months  Moved within 6 months Moved within 12 months 
 Unadjusted Adjusted Unadjusted Adjusted Unadjusted Adjusted 
 RR 95% CI aRR 95% CI RR 95% CI aRR 95% CI RR 95% CI aRR 95% CI 
(A) VL ≤50 copies/mL 
Moved 1.20 0.94 – 1.54 1.80 1.28 – 2.52 1.09 0.85 – 1.41 1.33 1.02 – 1.74 1.13 0.92 – 1.38 1.35 1.04 – 1.75 
Age 1.03 1.01 – 1.04 1.02 1.01 – 1.04 1.03 1.01 – 1.04 1.03 1.01 – 1.04 1.03 1.01 – 1.04 1.03 1.01 – 1.04 
Diagnosed with HIV in this 
pregnancy 
1.14 0.98 – 1.34 1.14 1.00 – 1.29 1.14 0.98 – 1.34 1.14 0.99 – 1.30 1.14 0.98 – 1.34 1.16 1.02 – 1.33 
Married/cohabiting 1.14 0.98 – 1.32 1.06 0.90 – 1.23 1.14 0.98 – 1.32 1.04 0.88 – 1.22 1.14 0.98 – 1.32 0.99 0.84 – 1.17 
Socioeconomic Status (Low) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 
Moderate 1.43 1.14 – 1.79 1.48 1.15 – 1.90 1.43 1.14 – 1.79 1.41 1.13 – 1.78 1.43 1.14 – 1.79 1.43 1.13 – 1.80 
High 1.32 1.05 – 1.67 1.31 1.02 – 1.69 1.32 1.05 – 1.67 1.25 0.99 – 1.58 1.32 1.05 – 1.67 1.26 0.99 – 1.59 
CD4 count at baseline (<200) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 
200-350 1.13 0.88 – 1.45 1.10 0.88 – 1.38 1.13 0.88 – 1.45 1.16 0.90 – 1.49 1.13 0.88 – 1.45 1.26 0.95 – 1.66  
350-500 1.01 0.76 – 1.33 1.02 0.80 – 1.29 1.01  0.76 – 1.33 1.07 0.82 – 1.39 1.01 0.76 – 1.33 1.16 0.87 – 1.53 
>500 1.17 0.91 – 1.52 1.36 1.09 – 1.70 1.17 0.91 – 1.52 1.40 1.08 – 1.80 1.17 0.91 – 1.52 1.48  1.12 – 1.96 
Design effect (intervention vs 
control arm) 
1.28 1.10 – 1.50 1.27 1.09 – 1.48 1.28 1.10 – 1.50 1.26 1.08 – 1.48 1.28 1.10 – 1.50 1.28 1.08 – 1.50 
(B) VL ≤1000 copies/mL 
Moved 1.22 1.03 – 1.44 1.74 1.32 – 2.29 1.14 0.95 – 1.37 1.32 1.07 – 1.62 1.15 0.99 – 1.34 1.37 1.10 – 1.71 
Age 1.02 1.01 – 1.03 1.01 1.00 – 1.02 1.02 1.01 – 1.03 1.02 1.01 – 1.03 1.02 1.01 – 1.03 1.02 1.01 – 1.03 
Diagnosed with HIV in this 
pregnancy 
1.15 1.02 – 1.31 1.12 1.00 – 1.25 1.15 1.02 – 1.31 1.10 0.98 – 1.24 1.15 1.02 – 1.31 1.13 1.01 – 1.27 
Married/cohabiting 1.13 1.00 – 1.28 0.99 0.88 – 1.13 1.13 1.00 – 1.28 1.03 0.91 – 1.17 1.13 1.00 – 1.28 1.00 0.88 – 1.14 
Socioeconomic Status (Low) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 
Moderate 1.26 1.05 – 1.50 1.28 1.05 – 1.55 1.26 1.05 – 1.50 1.20 1.00 – 1.44 1.26 1.05 – 1.50 1.20 0.99 – 1.44 
High 1.18 0.99 – 1.42 1.11 0.93 – 1.34 1.18 0.99 – 1.42 1.06 0.89 – 1.26 1.18 0.99 – 1.42 1.05 0.88 – 1.26 
CD4 count at baseline (<200) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 
200-350 1.12 0.90 – 1.39 1.19 0.98 – 1.43 1.12 0.90 – 1.39 1.19 0.96 – 1.49 1.12 0.90 – 1.39 1.30 1.02 – 1.65 
350-500 1.02 0.80 – 1.30 1.14 0.92 – 1.40 1.02 0.80 – 1.30 1.11 0.88 – 1.39 1.02 0.80 – 1.30 1.20 0.95 – 1.53 
>500 1.24 1.01 – 1.53 1.45 1.17 – 1.79 1.24 1.01 – 1.53 1.45 1.14 – 1.85 1.24 1.01 – 1.53 1.56 1.19 – 2.04 
Design effect (intervention vs 
control arm) 
1.13 0.99 – 1.28 1.17 1.03 – 1.33 1.13 0.99 – 1.28 1.15 1.01 – 1.31 1.13 0.99 – 1.28 1.16 1.01 – 1.32 
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Table 4. Log binomial regression model among 349 postpartum women living with HIV who initiated ART during pregnancy, predicting A) VL ≤50 copies/mL at 
approximately 4 years postpartum, and B) VL ≤1000 copies/mL at approximately 4 years postpartum. This table is grouped by whether movement occurred 3 months, 
6 months or 12 months prior to the viral load visit. Unadjusted (RR) and adjusted (aRR) risk ratios are presented with 95% confidence intervals (CI). 
 
 Moved within 3 months Moved within 6 months Moved within 12 months 
 Unadjusted Adjusted Unadjusted Adjusted Unadjusted Adjusted  
 RR 95% CI aRR 95% CI  RR 95% CI aRR 95% CI RR 95% CI aRR 95% CI 
(A) VL ≤50 copies/mL 
Moved 0.83 0.43 – 1.59 0.89 0.45 – 1.74 0.97 0.60 – 1.58 1.09 0.67 – 1.77 0.67 0.42 – 1.05 0.72 0.45 – 1.14 
Age 1.02 1.00 – 1.03 1.01 0.99 – 1.03 1.02 1.00 – 1.03 1.01 0.99 – 1.03 1.02 1.00 – 1.03 1.01 0.99 – 1.03 
Married/cohabiting 1.28 1.07 – 1.53 1.20 0.99 – 1.45 1.28 1.07 – 1.53 1.20 0.99 – 1.45 1.28 1.07 – 1.53 1.21 1.00 – 1.46 
Employed 1.21 1.01 – 1.45 1.24 1.03 – 1.48 1.21 1.01 – 1.45 1.24 1.03 – 1.48 1.21 1.01 – 1.45 1.23 1.03 – 1.47 
Currently pregnant 1.40 1.07 – 1.83 1.39 1.06 – 1.82 1.40 1.07 – 1.83 1.40 1.07 – 1.83 1.40 1.07 – 1.83 1.34 1.01 – 1.79 
Design effect (intervention 
vs control arm) 
0.91 0.76 – 1.09 0.90 0.76 – 1.08 0.91 0.76 – 1.09 0.90 0.75 – 1.07 0.91 0.76 – 1.09 0.93 0.78 – 1.11  
(B) VL ≤1000 copies/mL 
Moved 1.14 0.79 – 1.64 1.26 0.85 – 1.87 1.15 0.84 – 1.57 1.29 0.93 – 1.80 0.87 0.63 – 1.19 0.94 0.68 – 1.29 
Age 1.01 0.99 – 1.02 1.01 0.99 – 1.02 1.01 0.99 – 1.02 1.01 0.99 – 1.02 1.01 0.99 – 1.02 1.01 0.99 – 1.02 
Married/cohabiting 1.24 1.07 – 1.43 1.15 0.97 – 1.36 1.24 1.07 – 1.43 1.16 0.98 – 1.37 1.24 1.07 – 1.43 1.15 0.97 – 1.35 
Employed 1.15 0.99 – 1.33 1.17 0.99 – 1.36 1.15 0.99 – 1.33 1.17 1.00 – 1.36 1.15 0.99 – 1.33 1.17 1.00 – 1.37 
Currently pregnant 1.35 1.10 – 1.65 1.41 1.09 – 1.81 1.35 1.10 – 1.65 1.41 1.09 – 1.81 1.35 1.10 – 1.65 1.38 1.08 – 1.78 
Design effect (intervention 
vs control arm) 
0.93 0.80 – 1.09 0.97 0.83 – 1.12 0.93 0.80 – 1.09 0.96 0.83 – 1.12 0.93 0.80 – 1.09 0.96 0.83 – 1.11 
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Mobility and retention in HIV care 
The retention analysis was restricted to 315 women who did not report leaving the Western Cape. 
Of these women, 79% and 68% were retained in care at 12 months and 4 years postpartum, 
respectively. Retention in care at both 12 months and 4 years postpartum was not associated with 
having moved within 3, 6 or 12 months of the measurement visit (Table 5). The MCH-ART trial 
arm did not alter any of the associations for the retention in care outcome. Moderate SES was 
associated with increased likelihood of being retained in care in comparison to low SES for the 12 
months (aRR=1.23, 95% CI: 1.04-1.45) and 4 years (aRR=1.25, 95% CI: 1.02-1.52) postpartum 
models, while the association with high SES (aRR=1.38, 95% CI: 1.13-1.67) was only statistically 
significant at 4 years postpartum. Age (aRR=1.01, 95% CI: 1.00-1.02) was associated with being 
retained in care at 12 months postpartum, while being married (aRR=1.20, 95% CI: 1.08-1.32) 
increased the likelihood of being retained in care at 12 months postpartum. Being currently 
pregnant (aRR=1.52, 95% CI: 1.18-1.97) increased the likelihood of being retained in care at 4 
years postpartum. Having a higher CD4 count at baseline decreased the likelihood of being 
retained at 4 years postpartum in comparison to a CD4 count of <200, however this association 
was only statistically significant for a CD4 count of >500 (aRR=0.79, 95% CI: 0.64-0.99).
15 | M a n u s c r i p t  
 
 
Table 5. Log binomial regression model among 315 postpartum women living with HIV who initiated ART during pregnancy, predicting A) retention in care at 
approximately 12 months postpartum, and B) retention in care at approximately 4 years postpartum (Restricted to women who did not report moving out of the Western 
Cape). This table is grouped by whether movement occurred 3 months, 6 months or 12 months prior to the viral load visit. Unadjusted (RR) and adjusted (aRR) risk ratios 
are presented with 95% confidence intervals (CI). 
 
 Moved within 3 months Moved within 6 months Moved within 12 months 
 Unadjusted Adjusted Unadjusted Adjusted Unadjusted Adjusted 
 RR 95% CI aRR 95% CI RR 95% CI aRR 95% CI RR 95% CI aRR 95% CI 
(A) Retained at 12 months postpartum 
Moved 1.09 0.88 – 1.34 1.10 0.94 – 1.28 1.06 0.86 – 1.29 1.09 0.94 – 1.26 1.11 0.95 – 1.30 1.12 0.99 – 1.28 
Age 1.01 0.99 – 1.02 1.01 1.00 – 1.02 1.01 0.99 – 1.02 1.01 1.00 – 1.02 1.01 0.99 – 1.02 1.01 1.00 – 1.02 
Married/cohabiting 1.17 1.05 – 1.30 1.20 1.08 – 1.32 1.17 1.05 – 1.30 1.20 1.08 – 1.32 1.17 1.05 – 1.30 1.20  1.09 – 1.33 
Socioeconomic Status (Low) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 
Moderate 1.19 1.01 – 1.39 1.23 1.04 – 1.45 1.19 1.01 – 1.39 1.23 1.04 – 1.45 1.19 1.01 – 1.39 1.24 1.04 – 1.47 
High 1.09 0.92 – 1.28 1.18 0.99 – 1.39 1.09 0.92 – 1.28 1.17 0.99 – 1.39 1.09 0.92 – 1.28 1.71 0.99 – 1.39 
CD4 count at baseline (<200) 1 (ref) - - 1 (ref) - - 1 (ref) - - 
200-350 0.98 0.83 – 1.16 - - 0.98 0.83 – 1.16 - - 0.98 0.83 – 1.16 - - 
350-500 0.99 0.84 – 1.18 - - 0.99 0.84 – 1.18 - - 0.99 0.84 – 1.18 - - 
>500 0.90 0.74 – 1.08 - - 0.90 0.74 – 1.08 - - 0.90 0.74 – 1.08 - - 
Design effect (intervention vs 
control arm) 
1.17 1.04 – 1.31 1.20 1.09 – 1.33 1.17 1.04 – 1.31 1.20 1.09 – 1.32 1.17 1.04 – 1.31 1.20 1.09 – 1.32 
(B) Retained at 4 years postpartum 
Moved 0.59 0.20 – 1.72 0.57 0.20 – 1.67 0.82 0.45 – 1.47 0.83 0.47 – 1.47 0.88 0.61 – 1.27 0.84 0.58 – 1.21 
Age 0.99 0.99 – 1.01 - - 0.99 0.99 – 1.01 - - 0.99 0.99 – 1.01 - - 
Married/cohabiting 1.06 0.91 – 1.23 - - 1.06 0.91 – 1.23 - - 1.06 0.91 – 1.23 - - 
Currently pregnant 1.35 1.13 – 1.60 1.54 1.20 – 1.98 1.35 1.13 – 1.60 1.52 1.18 – 1.97 1.35 1.13 – 1.60 1.53 1.21 – 1.94 
Socioeconomic Status (Low) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 
Moderate 1.22 0.99 – 1.51 1.27 1.04 – 1.54 1.22 0.99 – 1.51 1.25 1.02 – 1.52 1.22 0.99 – 1.51 1.23 1.02 – 1.49 
High 1.30 1.06 – 1.58 1.39 1.14 – 1.69 1.30 1.06 – 1.58 1.38 1.13 – 1.67 1.30 1.06 – 1.58 1.34 1.11 – 1.62 
CD4 count at baseline (<200) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 
200-350 0.99 0.82 -1.19 1.08 0.88 – 1.32 0.99 0.82 -1.19 1.08 0.88 – 1.33 0.99 0.82 -1.19 1.09  0.89 – 1.33 
350-500 0.83 0.66 – 1.04 0.90 0.81 – 1.13 0.83 0.66 – 1.04 0.90 0.71 – 1.14 0.83 0.66 – 1.04 0.89  0.71 – 1.13 
>500 0.75 0.59 – 0.95 0.79 0.63 – 0.98 0.75 0.59 – 0.95 0.79 0.64 – 0.99 0.75 0.59 – 0.95 0.79 0.64 – 0.98 
Design effect (intervention vs 
control arm) 
1.02 0.88 – 1.19 1.03 0.88 – 1.19 1.02 0.88 – 1.19 1.03 0.88 – 1.19 1.02 0.88 – 1.19 1.03 0.89 – 1.20 
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Discussion        
This study describes the mobility patterns and HIV treatment outcomes of postpartum women who 
initiated lifelong ART during their pregnancy and were followed for up to 4 years postpartum. 
Overall, movement was common and mostly occurred in the first 12 months postpartum, with 28% 
of women reporting having moved to a different location at least once during the postpartum 
period. This analysis suggests that movement was not associated with viral suppression or 
retention in care at 4 years postpartum. At 12 months postpartum, women who had moved within 
3, 6 or 12 months of the VL measurement were more likely to be virally suppressed compared to 
women who had not moved. No associations between mobility and VL at 4 years, or retention at 
either time point, were observed. These findings highlight high levels of viraemia and non-
retention at both 12 months and 4 years postpartum, however mobility does not appear to be a key 
determinant of this specifically at 4 years postpartum.  
 
Our finding that movement following delivery is a common occurrence among women living with 
HIV supports previous studies that have shown mobility in the postpartum period, mostly 
occurring right after the delivery of the baby [2,6–8,13,22]. Clouse and colleagues’ [6] study 
among South African peripartum women found that nearly all of their participants planned to travel 
after delivery. Our findings suggest a key reason for movement is to seek care and help with the 
baby from family, which is consistent with the findings of previous studies on postpartum mobility 
and loss to follow up (LTFU) [6,13,22].  
 
Despite the concerning levels of viraemia at 12 months and 4 years postpartum (34% and 44%, 
respectively), moving does not appear to be associated with worse viral load outcomes in our study. 
The only significant association was that movement within 3, 6 or 12 months of the VL 
measurement at 12 months postpartum increased the likelihood of being suppressed. The observed 
difference in proportions were however very low (7%, 8% and 12% mobility in the suppressed 
versus 4%, 6% and 9% in the unsuppressed). In contrast, previous studies have shown movement 
to be associated with suboptimal treatment adherence and poor treatment outcomes including 
being less likely to be suppressed [3,21,23–26]. One explanation may be the focus on different 
populations, with these studies focusing on migrant populations who mostly travelled for work. 
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There were great variations in the definitions for mobility used in these studies, with mobility 
being defined as either permanent or temporary migration, cross-border migration, and frequent 
migration. This variation in definitions of mobility in literature has been shown to contribute to 
the inconsistent findings on mobility and its impact on HIV treatment outcomes [5,21].  
 
The association between mobility and viral suppression at 12 months postpartum may be linked to 
the main reported reason for moving which was to seek help with care for the baby from family. 
While some studies have shown this to be a hindrance to adequate engagement with HIV care, 
family support has also been shown to be an important facilitator [20,27]. Support from the family 
has been shown to be an enabler of ART adherence, mainly by helping women with domestic tasks 
and caring for the baby thereby making it possible for them to attend their clinic appointments 
[20,27]. We hypothesize that women who moved for support with the child may have also received 
social support to remain in HIV care. 
 
High levels of non-retention at 12 months and 4 years postpartum (21% versus 32%) were 
observed in this analysis. Despite these findings, movement in the postpartum period was not 
associated with retention in care for our participants. Nonetheless, these high levels of non-
retention reflect previous observations that women are at high risk of disengagement from care 
particularly following delivery [13,20,22,28,29]. Studies on retention among postpartum women 
have shown that moving may increase the risk of disengagement from care [9,13,28,30,31]. 
Although mobility was not associated with poor retention in care in this study, the high levels of 
non-retention found warrants further effort to ensure continuity of care for mobile populations.  
 
Previous literature on postpartum women’s engagement with HIV care has shown that following 
delivery mothers often emphasize care for the infant over care for the mother, overlooking the 
importance of continuous care for themselves [6,7]. Pregnancy and ANC has are important points 
for entry and re-entry into HIV services [32–34]. Our findings showed that women who were 
pregnant at 4 years postpartum were more likely to be virally suppressed and retained in care. This 
adds to previous findings that women are more likely to be adherent to ART and retained in care 
throughout pregnancy in order to protect their baby but then discontinuing care in the postpartum 
period [7]. Another predictor of viral suppression in this study was older age. This supports the 
18 | M a n u s c r i p t  
 
extensive evidence that younger women have an increased risk of poor treatment outcomes 
[9,10,20,31].  
 
When interpreting these findings, it is important to consider several limitations. The main 
limitation of these results is that all data collected on the primary exposure (mobility) was self-
reported by study participants. Participants had to report their mobility over the 4 year period 
following delivery, therefore this data may be susceptible to recall bias and could have led to errors 
in recalling movement and the timing thereof. Analyses using different windows of having moved 
within 3, 6 and 12 months of the outcome measurement was done in an attempt to address some 
of the bias that could have arisen. While these women were recruited from a large primary care 
clinic in Cape Town and these findings may be generalizable to similar settings, they do not 
necessarily reflect the mobility and HIV care experiences of women in other areas in South Africa 
or sub-Saharan Africa.  It is important to note that the retention data was limited to women who 
did not move out of the Western Cape. This data was drawn from routine medical records obtained 
from the Western Cape Department of Health’s Provincial Health Data Centre, which is only able 
to link participants’ healthcare access across public facilities in the Western Cape [18]. Therefore, 
estimates of LTFU may not represent true disengagement from care and could result in an 
underestimation of retention, specifically for women who are required to transfer care in the 
postpartum period.  
 
This study contributes to the scarce literature on postpartum women’s mobility and how it effects 
their HIV care engagement and treatment outcomes. It is important to provide more insight on the 
role that postpartum mobility plays in terms of engagement with care, as consistent retention in 
care is a significant challenge in South Africa, specifically for postpartum women [6]. Continuous 
engagement in care for postpartum women is of great importance as HIV requires lifelong 
treatment and high treatment adherence in order to prevent treatment failure [16,35]. These 
findings show that movement following delivery is common, but this did not seem to disrupt 
engagement in HIV care. This study’s findings emphasize the need for further research on 
postpartum mobility and its impact on women’s treatment outcomes and retention in care in order 
for healthcare facilities to adequately consider movement and adapt care for this population.  
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Supporting Information  
Additional supplementary tables may be found in the appendix section of this article (Appendix 
G). 
Table 1. Bivariate statistics of covariates of 353 postpartum women living with HIV who 
initiated ART during pregnancy. This table is grouped by whether they had moved within 6 
months of the viral load visit or not during the postpartum period at approximately 12 months 
and 4 years following delivery. The characteristics were measured at baseline and 4 years 
postpartum for the two groups, respectively. 
Table 2. Bivariate statistics of covariates of 349 postpartum women living with HIV who 
initiated ART during pregnancy. This table is grouped by whether they were virally suppressed 
(VL ≤50 copies/mL) or not during the postpartum period at approximately 12 months and 4 
years following delivery. 
Table 3. Bivariate statistics of covariates of 349 postpartum women living with HIV who 
initiated ART during pregnancy. This table is grouped by whether they were virally suppressed 
(VL ≤1000 copies/mL) or not during the postpartum period at approximately 12 months and 4 
years following delivery. 
Table 4. Bivariate statistics of covariates of 315 postpartum women living with HIV who 
initiated ART during pregnancy (Restricted to women who did not report moving out of the 
Western Cape). This table is grouped by whether they were retained in HIV care or not during 
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Appendix G: Supporting Information - Supplementary Tables 
 
 
Table 1. Bivariate statistics of covariates of 353 postpartum women living with HIV who initiated ART during pregnancy. 
This table is grouped by whether they had moved within 6 months of the viral load visit or not during the postpartum period 
at approximately 12 months and 4 years following delivery. The characteristics were measured at baseline and 4 years 
postpartum for the two groups, respectively. 
 
 12 months postpartum 4 years postpartum 
Variable 
Moved Did Not 
Moved 
p-value Moved Did Not 
Move 
p-value 
Age (mean and standard deviation) 30.14 (5.17) 30.04 (5.59) 0.929 31.23 (5.26) 32.58 (5.49) 0.351 
Married/ cohabiting  12 (46) 123 (38) 0.423 5 (33) 140 (38) 0.701 
Completed secondary school 3 (12) 78 (24) 0.255 2 (13) 90 (25) 0.538 
Employed 9 (35) 124 (39) 0.694 6 (40) 158 (43) 0.808 
Gravidity (median and IQR) 1 (1-2) 1 (1-2) 0.705 2 (1-3) 2.5 (2-3) 0.208 
Diagnosed with HIV in this pregnancy 13 (50) 172 (53) 0.737 9 (60) 198 (54) 0.653 
Currently Pregnant 0 (0) 2 (1) 1.000 1 (7) 20 (6) 0.580 
Socioeconomic Status   0.080   0.758 
Lowest 11 (42) 81 (25)  5 (33) 128 (35)  
Moderate 10 (39) 118 (37)  6 (40) 112 (31)  
Highest 5 (19) 123 (38)  4 (27) 126 (34)  
Formal housing 9 (35) 160 (50) 0.139 8 (53) 185 (51) 0.832 
CD4 count at baseline   0.797   0.952 
<200 6 (23) 51 (16)  2 (13) 59 (17)  
200-350 7 (27) 107 (34)  6 (40) 113 (32)  
350-500 6 (23) 75 (24)  3 (20) 90 (25)  
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Table 2. Bivariate statistics of covariates of 349 postpartum women living with HIV who initiated ART during pregnancy. This 
table is grouped by whether they were virally suppressed (VL ≤50 copies/mL) or not during the postpartum period at 
approximately 12 months and 4 years following delivery. 











Age (mean and standard deviation) 30.87 (5.48) 28.43 (5.45) 0.000 33.15 (5.19) 31.77 (5.74) 0.014 
Moved within 6 months of outcome visit 18 (8) 7 (6) 0.537 8 (4) 7 (4) 0.910 
Moved within 3 months of outcome visit 15 (7) 4 (4) 0.320 5 (2) 6 (4) 0.529 
Moved within 12 months of outcome visit 28 (12) 10 (9) 0.312 12 (6) 20 (12) 0.040 
Married/ cohabiting  95 (42) 38 (32) 0.092 91 (44) 53 (31) 0.010 
Completed secondary school 59 (26) 23 (20) 0.193 55 (27) 36 (21) 0.223 
Employed 97 (42) 38 (32) 0.066 99 (48) 64 (37) 0.042 
Gravidity (median and IQR) 1 (1-2) 1 (1-2) 0.167 2 (2-3) 2 (2-3) 0.842 
Diagnosed with HIV in this pregnancy 131 (57) 56 (48) 0.084 115 (56) 90 (53) 0.570 
Currently Pregnant 1 (1) 1 (1) 0.547 15 (7) 5 (3) 0.068 
Socioeconomic Status 0.003 0.458 
Lowest 46 (20) 43 (36) 66 (32) 65 (38) 
Moderate 95 (42) 34 (29) 67 (32) 51 (30) 
Highest 88 (38) 41 (35) 74 (36) 55 (32) 
Formal housing 106 (46) 64 (54) 0.161 98 (47) 92 (54) 0.211 
CD4 count at baseline 0.424 0.828 
<200 33 (15) 22 (19) 33 (16) 28 (17) 
200-350 77 (35) 37 (32) 62 (31) 55 (33) 
350-500 49 (22) 32 (27) 55 (27) 38 (23) 
>500 62 (28) 26 (22) 53 (26) 45 (27) 
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Table 3. Bivariate statistics of covariates of 349 postpartum women living with HIV who initiated ART during pregnancy. This 
table is grouped by whether they were virally suppressed (VL ≤1000 copies/mL) or not during the postpartum period at 
approximately 12 months and 4 years following delivery. 
 











Age (mean and standard deviation) 30.66 (5.52) 28.24 (5.37) 0.000 32.94 (5.24) 31.76 (5.85) 0.044 
Moved within 6 months of outcome visit 21 (8) 4 (5) 0.343 11 (5) 4 (3) 0.587 
Moved within 3 months of outcome visit 17 (7) 2 (2) 0.176 8 (3) 3 (2) 0.753 
Moved within 12 months of outcome visit 32 (13) 6 (7) 0.145 18 (7) 14 (10) 0.321 
Married/ cohabiting  106 (41) 26 (30) 0.051 105 (43) 39 (29) 0.006 
Completed secondary school 62 (24) 19 (22) 0.628 61 (25) 30 (22) 0.555 
Employed 105 (41) 28 (32) 0.133 113 (47) 50 (37) 0.075 
Gravidity (median and IQR) 1 (1-2) 1 (1-2) 0.132 3 (2-3) 2 (2-3) 0.375 
Diagnosed with HIV in this pregnancy 147 (57) 38 (43) 0.023 137 (56) 68 (50) 0.261 
Currently Pregnant 2 (1) 0 (0) 1.000 17 (7) 3 (2) 0.055 
Socioeconomic Status   0.022   0.895 
    Lowest 57 (22) 32 (36)  83 (34) 48 (36)  
    Moderate 103 (40) 25 (28)  75 (31) 43 (32)  
    Highest 97 (38) 31 (35)  85 (35) 44 (33)  
Formal housing 119 (46) 50 (57) 0.089 115 (47) 75 (56) 0.125 
CD4 count at baseline    0.089   0.898 
    <200 36 (15) 18 (21)  37 (16) 24 (18)  
    200-350 85 (34) 29 (33)  75 (32) 42 (32)  
    350-500 55 (22) 26 (30)  61 (26) 32 (24)  
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Table 4. Bivariate statistics of covariates of 315 postpartum women living with HIV who initiated ART during pregnancy 
(Restricted to women who did not report moving out of the Western Cape). This table is grouped by whether they were retained 
in HIV care or not during the postpartum period at approximately 12 months and 4 years following delivery. 




p-value Retained Not 
Retained 
p-value
Age (mean and standard deviation) 30.21 (5.61) 29.10 (5.45) 0.164 32.53 (5.16) 32.57 (6.37) 0.943 
Moved within 6 months of outcome visit 16 (7) 3 (5) 0.775 5 (2) 4 (4) 0.476 
Moved within 3 months of outcome visit 13 (5) 2 (3) 0.744 2 (1) 3 (3) 0.333 
Moved within 12 months of outcome visit 22 (9) 3 (5) 0.434 12 (6) 8 (8) 0.441 
Married/ cohabiting  111 (44) 18 (26) 0.008 92 (42) 39 (38) 0.441 
Completed secondary school 63 (25) 18 (26) 0.827 64 (29) 18 (18) 0.024 
Employed 97 (38) 31 (45) 0.310 116 (53) 37 (36) 0.003 
Gravidity (median and IQR) 1 (1-2) 1 (1-2) 0.166 2 (2-3) 2.5 (2-4) 0.291 
Diagnosed with HIV in this pregnancy 131 (52) 41 (59) 0.247 112 (51) 60 (58) 0.270 
Currently Pregnant 0 (0) 2 (1) 1.000 17 (8) 2 (2) 0.042 
Socioeconomic Status 0.082 0.022 
    Lowest 58 (23) 23 (33) 58 (27) 43 (41) 
    Moderate 95 (37) 17 (25) 71 (32) 30 (29) 
    Highest  101 (40) 29 (42) 90 (41) 31 (30) 
Formal housing 131 (52) 36 (52) 0.930 106 (48) 55 (53) 0.452 
CD4 count at baseline 0.550 0.022 
    <200 39 (16) 9 (13) 37 (17) 11 (11) 
200-350 83 (34) 21 (31) 79 (37) 25 (25) 
350-500 63 (26) 15 (22) 50 (23) 28 (28) 
>500 62 (25) 23 (34) 49 (23) 36 (36) 
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and/or analysis of the results. 
 
Discussion 
In the Discussion section, you should discuss your main findings and place these within the 
context of the current body of knowledge in the field. Limitations of the study, for example, 
selection bias, can also be discussed, and should address how these influence the results and 
conclusions. If statistically significant differences were found between men and women or 
between different racial or cultural groups in the effects of the studied intervention, the 
implications, if any, for clinical and/or public health should be adequately discussed. 
 
Conclusions 
In your Conclusions section, state your key messages from the study and explain their 
importance and relevance, as well as implications. Future studies and recommendations can be 
included in this section. The conclusions drawn must be strictly based on the data provided. 
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authors prior to publication and these should be clearly cited as such. If a table spans more than 
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data accessibility statement, including a link to the repository they have used, to accompany their 
paper. 
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manuscript, and the accession number, together with the database where the information was 
deposited, should be cited in square brackets in the text, for example, [EMBL:AB026295, 
EMBL:AC137000, DDBJ:AE000812, GenBank:U49845, PDB:1BFM, Swiss-Prot:Q96KQ7, 
PIR:S66116]. Relevant databases are: EMBL Nucleotide Sequence Database (EMBL), DNA 
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Standards Initiative Mass Spectrometry Standards Working Group guidelines. The data 
should also be deposited in the ProteomeExchange through the PRIDE website, and protein 
interaction data can be deposited through members of the IMEx consortium. 
 
Structures 
Protein structures can be submitted with one of the members of the Worldwide Protein Data 
Bank. Nucleic acid structures can be deposited with the Nucleic Acid Database at Rutgers. 
Crystal structures of organic compounds can be deposited with the Cambridge 
Crystallographic Data Centre. 
 
Chemical structures and assays 
Structures of chemical substances can be deposited with PubChem Substance. Bioactivity 
screens of chemical substances can be deposited with PubChem BioAssay. 
 
Functional genomics data (such as microarray or CHIP-Seq data) 
Please refer to standards proposed by the Functional Genomics Data Society and deposit 
your microarray data in MIAME-compliant format in one of the public repositories, for 
example, ArrayExpress or Gene Expression Omnibus (GEO). Deposition of high-throughput 
functional genomics sequencing data (such as RNA-Seq or ChIP-Seq data) with ArrayExpress or 
GEO in compliance with MINSEQE is also needed. 
Computational modelling 
Please prepare models of biochemical reaction networks using the Systems Biology Markup 
Language and submit your model to the BioModels database, as well as providing it as an 
additional file with your submission. 
 
Plasmids 
Please submit copies of your plasmids as DNA or bacterial stocks with Addgene, a non-profit 
repository, or PlasmID, the Plasmid Information Database at Harvard. 
Ethical approval – Human and animal studies 
 
Human Studies and Subjects 
For manuscripts reporting medical studies that involve human participants, a statement 
identifying the ethics committee that approved the study and confirmation that the study 
conforms to recognized standards is required, for example: Declaration of Helsinki; US Federal 
Policy for the Protection of Human Subjects; or European Medicines Agency Guidelines 
for Good Clinical Practice. 
A statement on the ethical aspects, including the consent procedure followed, must be included 
in the Methods section of the manuscript. The Editors may reject manuscripts where the 
research has not been carried out within an ethical framework. Images and information from 
individual participants will only be published where the authors have obtained the individual's free 
prior informed consent. Confidentiality of study participants must be ensured at all stages of 
research and reporting. Authors do not need to provide a copy of the consent form to the 
publisher; however, in signing the author license to publish, authors are required to confirm that 
consent has been obtained. Wiley has a standard patient consent form available for use. 
Animal Studies 
A statement indicating that the protocol and procedures employed were ethically reviewed and 
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approved, as well as the name of the body giving approval, must be included in the Methods 
section of the manuscript. Authors are encouraged to adhere to animal research reporting 
standards, for example the The Gold Standard Publication Checklist from Hooijmans and 
colleagues or the ARRIVE reporting guidelines for reporting study design and statistical 
analysis; experimental procedures; experimental animals and housing and husbandry. Authors 
should also state whether experiments were performed in accordance with relevant institutional 
and national guidelines for the care and use of laboratory animals: 
• US authors should cite compliance with the US National Research Council's Guide for the 
Care and Use of Laboratory Animals, the US Public Health Service's Policy on Humane Care 
and Use of Laboratory Animals, and Guide for the Care and Use of Laboratory Animals. 
• UK authors should conform to UK legislation under the Animals (Scientific Procedures) Act 
1986 Amendment Regulations (SI 2012/3039). 
• European authors outside the UK should conform to Directive 2010/63/EU. 
Clinical Trial Registration 
The journal requires that clinical trials are prospectively registered in a publicly accessible 
database and clinical trial registration numbers should be included in all papers that report their 
results. Authors are asked to include the name of the trial register and the clinical trial registration 
number at the end of the abstract. If the trial is not registered, or was registered retrospectively, 
the reasons for this should be explained. 
 
Research Reporting Guidelines 
Standard of reporting 
The JIAS endorses international standards of reporting. Please see the Uniform Requirements 
for Manuscripts Submitted to Biomedical Journals guidelines produced by ICMJE as a 
reference standard of reporting. Authors are also referred to the EQUATOR network website for 
further information on the available reporting guidelines for health research, and the MIBBI Portal 
for prescriptive checklists for reporting biological and biomedical research where applicable. A 
number of checklists are available for various study designs, including randomized controlled 
trials (CONSORT), interventional trials (SPIRIT), qualitative research (COREQ), systematic 
reviews (PRISMA), observational studies (STROBE), economic evaluations of health 
interventions (CHEERS), meta-analyses of observational studies (MOOSE) and diagnostic / 
prognostic studies (STARD and TRIPOD ). For systematic reviews, an additional file should be 
provided by the authors listing all details concerning the search strategy. Please refer to 
the Cochrane Reviewers' Handbook for an example of how a search strategy should be 
presented. 
 
Guidelines on mutation nomenclature are provided by the Human Genome Variation Society , 
and authors should use the recommended gene name by referring to the appropriate genetic 
nomenclature database, for example, HUGO for human genes, and the International Committee 
on Standardized Genetic Nomenclature for Mice. When describing human phenotypes, please 
use standardized terms, such as those proposed by the Elements of Morphology working group 
(see http://research.nhgri.nih.gov/morphology/index.cgi ). 
Contributions from pharmaceutical companies or other commercial organizations should follow 
the Good Publication Practice guidelinEs for pharmaceutical companies, which also apply 
to any companies or individuals that work on industry-sponsored publications, such as freelance 
writers, contract research organizations and communications companies. 
The JIAS supports international standards of reporting of trials, in particular, prospective 
registering and numbering of clinical trials. Clinical trials are defined by the World Health 
Organization as all phase I to IV trials, which are research studies that prospectively assign 
human participants or groups of humans to one or more health-related interventions to evaluate 
the effects on health outcomes. Trials need to be registered prior to submission in a suitable, 
publicly available registry. Links to existing registries can be found through ICMJE here or 
through the primary registers that participate in the WHO International Clinical Trials Registry 
Platform. The trial registration number should be included as the last line of the manuscript 
Abstract. 
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Reporting by gender and race 
Submitting authors shall include data disaggregated by sex (and, whenever possible, by race) 
and provide an analysis of gender and racial differences. The authors should include the number 
and percentage of men, women and, if appropriate, transgender persons, who participated in the 
research study. Anatomical and physiological differences between men and women (height, 
weight, body fat-to-muscle ratios, cell counts, hormonal cycles, etc.), as well as social and 
cultural variables (socio-economic, education, access to care, etc.), should be taken into 
consideration in the presentation of data and/or analysis of the results. If statistically significant 
differences were found between men and women or between different racial or cultural groups in 
the effects of the studied intervention, the implications, if any, for clinical and/or public health 
should be adequately discussed. If the research study was specific to one sex/gender, the 




Upon its first use in the title, abstract, and text, the common name of a species should be 
followed by the scientific name (genus, species, and authority) in parentheses. For well-known 
species, however, scientific names may be omitted from article titles. If no common name exists 
in English, only the scientific name should be used. 
Genetic Nomenclature 
Sequence variants should be described in the text and tables using both DNA and protein 
designations whenever appropriate. Sequence variant nomenclature must follow the current 
HGVS guidelines; see varnomen.hgvs.org, where examples of acceptable nomenclature are 
provided. 
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